SecBot SecBot
8-K ·Filed Sep 4, 2026

IONS

IONIS PHARMACEUTICALS INC
BEARISH
Impact 7/10
Horizonimmediate Processed2mo ago SEC0001140361-26-035802
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▼ Bearish

Expect a sharp negative stock reaction as the failure of a pivotal Phase 3 cardiovascular outcomes trial removes a major potential revenue driver. Monitor for analyst downgrades and potential pipeline revaluation. Ionis's other commercial medicines (TRYNGOLZA, DAWNZERA, ZANVASTRO) and pipeline may provide some offset, but the Lp(a) hypothesis setback is significant.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$56.71
T+0 close · Sep 4, 2026 · via day close
Latest settled
−22.41%
T+20 · $44.00 · next T+60 in 15d
Vs SPY
−24.13%
α at T+20
Latest observation
−45.79%
T+48 · FF3 residual α
  1. T+0 · Sep 8 $56.71entry
  2. T+1 · 2mo ago −1.22%α −0.75% · $56.02
  3. T+5 · 2mo ago −16.68%α −15.56% · $47.25
  4. T+20 · 6w ago −22.41%α −24.13% · $44.00
  5. T+49 · todayOpen
  6. T+60 · in 15d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ionis Pharmaceuticals announced that its partner Novartis reported the Phase 3 Lp(a)HORIZON study of pelacarsen did not meet its primary endpoint of reducing cardiovascular events in patients with elevated Lp(a) and established cardiovascular disease. The trial enrolled 8,323 patients and achieved substantial Lp(a) lowering but failed to translate into cardiovascular risk reduction. This is a major clinical setback for Ionis's partnered pipeline asset.

Key Facts

  • Phase 3 Lp(a)HORIZON study of pelacarsen did not meet its primary endpoint of reducing cardiovascular events (composite of CV death, non-fatal MI, non-fatal stroke, urgent coronary revascularization).
  • Trial enrolled 8,323 patients with elevated Lp(a) and established cardiovascular disease.
  • Pelacarsen substantially lowered Lp(a) levels but did not reduce cardiovascular risk.
  • Pelacarsen demonstrated an acceptable safety profile.
  • Ionis discovered and conducted early development; Novartis licensed rights in February 2019.
  • Full data will be presented at an upcoming medical congress.

Financial Impact

No financial figures provided in the filing. The failure likely eliminates future milestone and royalty payments from Novartis for pelacarsen, a key pipeline asset.

pipeline valuefuture revenue potential

Risk Factors

  • Further pipeline setbacks or negative readouts from other programs.
  • Dependence on Novartis for partnered programs may be reassessed.
  • Potential for broader negative sentiment on Lp(a) targeting therapies.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (32 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-035802
Document: ef20081690_ex99-1.htm0001140361-26-035802
Document: 0001140361-26-035802-index-headers.html0001140361-26-035802
Document: 0001140361-26-035802-index.html0001140361-26-035802
Document: 0001140361-26-035802.txt0001140361-26-035802

Track record

26 reports on IONS

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +32.25% at T+60 after the Jul 9, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Bearish 6/10 Entry $31.00 to $28.01 Now $28.01 +9.65% ▲ +9.65% +7.95% vs SPY
  2. Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $44.90 to $40.15 Now $28.01 −37.62% ▼ −10.58% −9.87% vs SPY
  3. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $42.93 to $43.52 Now $28.01 −34.75% ▲ +1.37% +1.93% vs SPY
  4. Oct 21, 202626d ago 8-K Bullish 7/10 Entry $43.91 to $44.39 Now $28.01 −36.21% ▲ +1.09% +0.39% vs SPY
  5. Oct 21, 202626d ago Institutional Cluster Mixed 3/10 Entry $43.91 to $44.39 Now $28.01 −36.21% ▲ +1.09% +0.39% vs SPY
  6. Sep 23, 20267w ago 8-K Bullish 7/10 Entry $43.93 to $44.65 Now $28.01 −36.24% ▲ +1.64% +2.31% vs SPY
  7. Sep 4, 202610w ago 8-K Bearish 7/10 Viewing Entry $56.71 to $47.25 Now $28.01 +50.61% ▲ +16.68% +15.56% vs SPY
  8. Sep 4, 202610w ago 8-K Bullish 7/10 Entry $58.09 to $51.44 Now $28.01 −51.78% ▼ −11.45% −10.24% vs SPY
  9. Jul 31, 202615w ago Insider Buy Neutral 4/10 Entry $54.49 to $56.94 Now $28.01 −48.60% ▲ +4.50% +2.47% vs SPY
  10. Jul 29, 202615w ago 8-K Neutral 5/10 Entry $54.04 to $54.19 Now $28.01 −48.17% ▲ +0.28% −5.25% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 4, 2026